تخطَّ إلى المحتوى
دليل الأدوية المصري
تابع آخر تحديثات الأسعار على واتساب

دواعي استعمال تايكرب 250مجم 70 قرص

معلومات من نشرات دوائية ومراجع موثقة، مع مصدر كل معلومة. السعر الحالي: 11,848ج.م.

عن الدواء

Tykerb (lapatinib) 250 mg film-coated tablets, pack of 70 (GlaxoSmithKline / Novartis).

دواعي الاستعمال
  • HER2-overexpressing advanced or metastatic breast cancer, in combination with capecitabineالفئة: Patients who received prior therapy including an anthracycline, a taxane and trastuzumabDailyMed (U.S. National Library of Medicine)
  • HR-positive, HER2-overexpressing metastatic breast cancer, in combination with letrozoleالفئة: Postmenopausal women for whom hormonal therapy is indicatedDailyMed (U.S. National Library of Medicine)
الآثار الجانبية
  • Most common with capecitabine (>20%): diarrhoea, palmar-plantar erythrodysaesthesia, nausea, rash, vomiting, fatigue. With letrozole (>=20%): diarrhoea, rash, nausea, fatigue.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
موانع الاستعمال
  • Known severe hypersensitivity (e.g. anaphylaxis) to the product or any of its components.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
تحذيرات واحتياطات
  • BOXED WARNING - hepatotoxicity: severe and sometimes fatal hepatotoxicity observed; monitor liver function and interrupt/discontinue if severe. Also: decreased LVEF (evaluate before and during treatment), severe diarrhoea, interstitial lung disease/pneumonitis, QT prolongation, severe cutaneous reactions, embryo-fetal toxicity.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائية
  • Strong CYP3A4 inhibitorsAvoid; if unavoidable consider reducing the lapatinib dose.DailyMed (U.S. National Library of Medicine)
  • Strong CYP3A4 inducersAvoid; if unavoidable consider gradual dose increase of lapatinib.DailyMed (U.S. National Library of Medicine)
  • Substrates of CYP3A4, CYP2C8 or P-glycoproteinLapatinib is likely to increase their exposure.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعة
  • Can cause fetal harm; advise females of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
  • Advise women not to breastfeed during treatment and for 1 week after the last dose.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

المصادر